Literature DB >> 10766308

The human papillomavirus type 16 E5 protein modulates ERK1/2 and p38 MAP kinase activation by an EGFR-independent process in stressed human keratinocytes.

K Crusius1, I Rodriguez, A Alonso.   

Abstract

The human papillomavirus type 16 E5 gene product has been shown to upregulate the activation of MAP kinases ERK1/2 and cellular proliferation promoted by EGF in a ligand-dependent process. We now report the growth factor-independent modulation of MAP kinases by HPV 16 E5 in human keratinocytes. After treatment with 600 mM sorbitol or low concentrations of anisomycin, E5-expressing cells upregulate the activation of ERK1/2. In addition, E5 enhances p38 activation after anisomycin but not after sorbitol treatment, but it has no effect on MAP kinases activation after shocking the cells with 300 mM sodium chloride. The E5-mediated, sorbitol-dependent increase in ERK1/2 activation is EGF-independent and is only partially inhibited by tyrphostin AG1478, which is known to inhibit specifically EGF receptor activation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10766308     DOI: 10.1023/a:1008112207824

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  22 in total

1.  The human papillomavirus type 16 E5-protein modulates ligand-dependent activation of the EGF receptor family in the human epithelial cell line HaCaT.

Authors:  K Crusius; E Auvinen; B Steuer; H Gaissert; A Alonso
Journal:  Exp Cell Res       Date:  1998-05-25       Impact factor: 3.905

2.  Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation.

Authors:  A V Khokhlatchev; B Canagarajah; J Wilsbacher; M Robinson; M Atkinson; E Goldsmith; M H Cobb
Journal:  Cell       Date:  1998-05-15       Impact factor: 41.582

Review 3.  Mitogen-activated protein kinase pathways.

Authors:  M J Robinson; M H Cobb
Journal:  Curr Opin Cell Biol       Date:  1997-04       Impact factor: 8.382

4.  Ultraviolet light and osmotic stress: activation of the JNK cascade through multiple growth factor and cytokine receptors.

Authors:  C Rosette; M Karin
Journal:  Science       Date:  1996-11-15       Impact factor: 47.728

5.  The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes.

Authors:  S W Straight; B Herman; D J McCance
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

6.  p38/RK is essential for stress-induced nuclear responses: JNK/SAPKs and c-Jun/ATF-2 phosphorylation are insufficient.

Authors:  C A Hazzalin; E Cano; A Cuenda; M J Barratt; P Cohen; L C Mahadevan
Journal:  Curr Biol       Date:  1996-08-01       Impact factor: 10.834

Review 7.  Human papillomaviruses in the pathogenesis of anogenital cancer.

Authors:  H zur Hausen
Journal:  Virology       Date:  1991-09       Impact factor: 3.616

8.  The human papillomavirus (HPV)-6 and HPV-16 E5 proteins co-operate with HPV-16 E7 in the transformation of primary rodent cells.

Authors:  G F Valle; L Banks
Journal:  J Gen Virol       Date:  1995-05       Impact factor: 3.891

9.  The E5 gene from human papillomavirus type 16 is an oncogene which enhances growth factor-mediated signal transduction to the nucleus.

Authors:  P Leechanachai; L Banks; F Moreau; G Matlashewski
Journal:  Oncogene       Date:  1992-01       Impact factor: 9.867

10.  The E5 protein of HPV-6, but not HPV-16, associates efficiently with cellular growth factor receptors.

Authors:  M Conrad; D Goldstein; T Andresson; R Schlegel
Journal:  Virology       Date:  1994-05-01       Impact factor: 3.616

View more
  25 in total

1.  A role for HPV16 E5 in cervical carcinogenesis.

Authors:  John P Maufort; Anny Shai; Henry C Pitot; Paul F Lambert
Journal:  Cancer Res       Date:  2010-03-23       Impact factor: 12.701

2.  The anecdote of viral etiopathogenia in ameloblastoma and odontogenic keratocyst: Why don't we let it go?

Authors:  Bacem A E O Khalele
Journal:  J Oral Biol Craniofac Res       Date:  2017-04-14

3.  The human papillomavirus type 16 E5 protein impairs TRAIL- and FasL-mediated apoptosis in HaCaT cells by different mechanisms.

Authors:  Kirsten Kabsch; Angel Alonso
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

Review 4.  Human papillomavirus-16 E5 protein: oncogenic role and therapeutic value.

Authors:  Niladri Ganguly
Journal:  Cell Oncol (Dordr)       Date:  2012-01-20       Impact factor: 6.730

5.  Alternative splicing of human papillomavirus type-16 E6/E6* early mRNA is coupled to EGF signaling via Erk1/2 activation.

Authors:  Simone Rosenberger; Johanna De-Castro Arce; Lutz Langbein; Renske D M Steenbergen; Frank Rösl
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-29       Impact factor: 11.205

6.  Endoplasmic reticulum-localized human papillomavirus type 16 E5 protein alters endosomal pH but not trans-Golgi pH.

Authors:  Gary L Disbrow; John A Hanover; Richard Schlegel
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

7.  Phosphorylation of the human papillomavirus type 16 E1--E4 protein at T57 by ERK triggers a structural change that enhances keratin binding and protein stability.

Authors:  Qian Wang; Alan Kennedy; Papia Das; Pauline B McIntosh; Steven A Howell; Erin R Isaacson; Steven A Hinz; Clare Davy; John Doorbar
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

8.  Human papillomavirus 16 E5 oncogene contributes to two stages of skin carcinogenesis.

Authors:  John P Maufort; Sybil M Genther Williams; Henry C Pitot; Paul F Lambert
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

Review 9.  The E5 proteins.

Authors:  Daniel DiMaio; Lisa M Petti
Journal:  Virology       Date:  2013-05-31       Impact factor: 3.616

10.  Human Papillomavirus 16 E5 Inhibits Interferon Signaling and Supports Episomal Viral Maintenance.

Authors:  Matthew L Scott; Brittany L Woodby; Joseph Ulicny; Gaurav Raikhy; A Wayne Orr; William K Songock; Jason M Bodily
Journal:  J Virol       Date:  2020-01-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.